Bicyclol

Drug Profile

Bicyclol

Alternative Names: SY 801

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chinese Academy of Medical Sciences
  • Developer Beijing Union Pharmaceutical; Chinese Academy of Medical Sciences
  • Class Antineoplastics; Antivirals; Biphenyl compounds; Hepatoprotectants; Small molecules
  • Mechanism of Action Cytochrome P-450 enzyme system stimulants; Free radical scavengers; Gap junction modulators; Glutathione transferase stimulants; HSP70 heat shock protein stimulants; Protein kinase C inhibitors; Proto-oncogene protein c-myc stimulants; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fatty liver; Viral hepatitis
  • No development reported Liver cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Liver-cancer in China (PO, Tablet)
  • 13 Jul 2015 Bicyclol is covered by patent protection (Beijing Union website, July 2015)
  • 18 Nov 1996 Preclinical development for Viral hepatitis in China (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top